Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

Bibliographic Details
Main Author: Camões- Barbosa, Alexandre
Publication Date: 2020
Other Authors: Ribeiro, Inês Mendes, Medeiros, Luisa
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503
Summary: Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
id RCAP_1ff6edd85e0508aac898042f765e523d
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/11503
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke SpasticityParesia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVCBotulinum ToxinsType A/adverse effectsMuscle Weakness/etiologyUpper ExtremityFraqueza Muscular/etiologiaMembros SuperioresToxinas Botulínicas Tipo A/efeitos adversosBotulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.A toxina botulínica A foi aprovada para o tratamento da espasticidade em doentes pós-AVC. Os efeitos adversos são geralmente de dois tipos: efeitos adversos relacionados com a administração local de toxina botulínica A; e efeitos adversos sistémicos relacionados com a difusão à distância da toxina. A paresia muscular dos membros contralaterais após tratamento com toxina botulínica A é um efeito adverso raro. Descrevemos o caso de uma mulher de 33 anos de idade que recebia infiltrações regulares de toxina incobotulínica A por espasticidade dos membros direitos pós-AVC hemorrágico. Foi feita uma troca para toxina abobotulínica A com um factor de conversão global de 1:3,83. A doente apresentou parésia do membro superior contralateral, especialmente do músculo deltóide. A electroneuromiografia foi compatível com bloqueio neuromuscular devido a toxina botulínica A. Recuperou totalmente após oito meses. A troca entre diferentes formulações de toxina botulínica A deve exigir precaução na conversão das unidades. Efeitos adversos à distância podem surgir, incluindo parésia dos membros contralaterais.Ordem dos Médicos2020-11-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/mswordapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503oai:ojs.www.actamedicaportuguesa.com:article/11503Acta Médica Portuguesa; Vol. 33 No. 11 (2020): November; 761-764Acta Médica Portuguesa; Vol. 33 N.º 11 (2020): Novembro; 761-7641646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/5804https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10908https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10909https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11382https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11414Direitos de Autor (c) 2019 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessCamões- Barbosa, AlexandreRibeiro, Inês MendesMedeiros, Luisa2022-12-20T11:06:16Zoai:ojs.www.actamedicaportuguesa.com:article/11503Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:41:26.569819Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Paresia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVC
title Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
spellingShingle Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Camões- Barbosa, Alexandre
Botulinum Toxins
Type A/adverse effects
Muscle Weakness/etiology
Upper Extremity
Fraqueza Muscular/etiologia
Membros Superiores
Toxinas Botulínicas Tipo A/efeitos adversos
title_short Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_fullStr Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full_unstemmed Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_sort Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
author Camões- Barbosa, Alexandre
author_facet Camões- Barbosa, Alexandre
Ribeiro, Inês Mendes
Medeiros, Luisa
author_role author
author2 Ribeiro, Inês Mendes
Medeiros, Luisa
author2_role author
author
dc.contributor.author.fl_str_mv Camões- Barbosa, Alexandre
Ribeiro, Inês Mendes
Medeiros, Luisa
dc.subject.por.fl_str_mv Botulinum Toxins
Type A/adverse effects
Muscle Weakness/etiology
Upper Extremity
Fraqueza Muscular/etiologia
Membros Superiores
Toxinas Botulínicas Tipo A/efeitos adversos
topic Botulinum Toxins
Type A/adverse effects
Muscle Weakness/etiology
Upper Extremity
Fraqueza Muscular/etiologia
Membros Superiores
Toxinas Botulínicas Tipo A/efeitos adversos
description Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-02
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503
oai:ojs.www.actamedicaportuguesa.com:article/11503
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/11503
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/5804
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10908
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/10909
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11382
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/11503/11414
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/msword
application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 33 No. 11 (2020): November; 761-764
Acta Médica Portuguesa; Vol. 33 N.º 11 (2020): Novembro; 761-764
1646-0758
0870-399X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591128610308096